Mirati Therapeutics has reported initial data from the Phase II KRYSTAL-7 clinical trial and KRYSTAL-1 Phase Ib cohort analysing a 400mg twice daily dose of adagrasib plus pembrolizumab to treat first-line non-small cell lung cancer (NSCLC) patients.

In both trials, the combination treatment was analysed as a first-line therapy in patients harbouring a KRASG12C mutation across all PD-L1 subgroups. 

At a median follow-up of 3.5 months, 75 participants were enrolled and could be analysed for safety. 

According to the latest findings, a concurrent combination regimen of adagrasib plus pembrolizumab showed tolerability and feasibility. 

Grade 1-2, Grade 3, and Grade 4 treatment-related adverse events were reported in the trial while no Grade 5 events were seen.

The combination therapy offered favourable initial clinical activity across all PD-L1 subgroups, with a 49% objective response rate (ORR) in evaluable subjects who received a minimum of one on-study scan.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

An ORR and disease control rate (DCR) of 57% and 100%, respectively, were seen in seven evaluable subjects in the KRYSTAL-1 Phase Ib cohort.

Safety in the KRYSTAL-1 Phase 1b cohort was also in line with those seen in KRSTYAL-7, with a manageable safety profile.

An investigational oral small-molecule KRASG12C inhibitor, adagrasib showed to have a durable half-life and widespread tissue distribution in studies.

Pembrolizumab is a PD-1/L1 checkpoint inhibitor.

Mirati Therapeutics research and development head, president and founder Chuck Baum said: “We look forward to progressing our clinical development in the first-line setting, with a goal of providing better options for patients with NSCLC harbouring a KRASG12C mutation. 

“This data further underscores the potential of adagrasib as a well-tolerated treatment option for patients. Based on these data, we look forward to initiating a Phase III trial.”

In January this year, the company reported positive results from the Phase II KRYSTAL-1 trial of a 600mg twice daily dose of adagrasib in pre-treated pancreatic ductal adenocarcinoma and other gastrointestinal tumour patients with a KRAS-G12C mutation.

Clinical Trials Arena Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Clinical Trials Arena Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now